PURPOSE: Triptolide (TPL) is a diterpenoid triepoxide that effectively induces apoptosis in a wide variety of cancer cells. However, the detailed mechanism by which TPL activates caspase cascade remains elusive. This study aimed to examine the antitumor effects of TPL against pancreatic cancer and investigate the underlying mechanism. METHODS: Cell proliferation was evaluated by sulforhodamine B assay. The apoptosis was evaluated by caspase activity assay, Western blot and flow cytometry. DcR3 level was measured by ELISA. AsPC-1 xenografts were established to compare the in vivo antitumor effects of TPL and Gemcitabine. RESULTS: TPL inhibited the proliferation and induced the apoptosis of pancreatic cancer cells in a dose- and time-dependent manner. TPL also inhibited DcR3 expression in a dose- and time-dependent manner. siRNA-mediated DcR3 knockdown sensitized pancreatic cancer cells to TPL-induced apoptosis. In vivo, DcR3 siRNA significantly enhanced TPL-induced apoptosis and tumor growth inhibition. Moreover, TPL showed less toxicity compared to Gemcitabine in mice model. CONCLUSIONS: TPL induces the apoptosis of pancreatic cancer cells via the downregulation of DcR3 expression and has the potential as an effective agent against pancreatic cancer.
PURPOSE:Triptolide (TPL) is a diterpenoidtriepoxide that effectively induces apoptosis in a wide variety of cancer cells. However, the detailed mechanism by which TPL activates caspase cascade remains elusive. This study aimed to examine the antitumor effects of TPL against pancreatic cancer and investigate the underlying mechanism. METHODS: Cell proliferation was evaluated by sulforhodamine B assay. The apoptosis was evaluated by caspase activity assay, Western blot and flow cytometry. DcR3 level was measured by ELISA. AsPC-1 xenografts were established to compare the in vivo antitumor effects of TPL and Gemcitabine. RESULTS:TPL inhibited the proliferation and induced the apoptosis of pancreatic cancer cells in a dose- and time-dependent manner. TPL also inhibited DcR3 expression in a dose- and time-dependent manner. siRNA-mediated DcR3 knockdown sensitized pancreatic cancer cells to TPL-induced apoptosis. In vivo, DcR3 siRNA significantly enhanced TPL-induced apoptosis and tumor growth inhibition. Moreover, TPL showed less toxicity compared to Gemcitabine in mice model. CONCLUSIONS:TPL induces the apoptosis of pancreatic cancer cells via the downregulation of DcR3 expression and has the potential as an effective agent against pancreatic cancer.
Authors: J Zhang; T W Salcedo; X Wan; S Ullrich; B Hu; T Gregorio; P Feng; S Qi; H Chen; Y H Cho; Y Li; P A Moore; J Wu Journal: J Clin Invest Date: 2001-06 Impact factor: 14.808
Authors: Steffen Frese; Farzaneh Pirnia; Daniela Miescher; Stan Krajewski; Markus M Borner; John C Reed; Ralph A Schmid Journal: Oncogene Date: 2003-08-21 Impact factor: 9.867
Authors: Yulian Wu; Bing Han; Hongwei Sheng; Min Lin; Paul A Moore; Jun Zhang; Jiangping Wu Journal: Int J Cancer Date: 2003-07-10 Impact factor: 7.396
Authors: Bing Z Carter; Duncan H Mak; Wendy D Schober; Teresa McQueen; David Harris; Zeev Estrov; Randall L Evans; Michael Andreeff Journal: Blood Date: 2006-03-23 Impact factor: 22.113
Authors: Wei Wang; Shanmin Yang; Ying Su; Zhenyu Xiao; Chunyou Wang; Xinfeng Li; Ling Lin; Bruce M Fenton; Scott F Paoni; Ivan Ding; Peter Keng; Paul Okunieff; Lurong Zhang Journal: Clin Cancer Res Date: 2007-08-15 Impact factor: 12.531
Authors: Claudio Scafoglio; Bruce A Hirayama; Vladimir Kepe; Jie Liu; Chiara Ghezzi; Nagichettiar Satyamurthy; Neda A Moatamed; Jiaoti Huang; Hermann Koepsell; Jorge R Barrio; Ernest M Wright Journal: Proc Natl Acad Sci U S A Date: 2015-07-13 Impact factor: 11.205